Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 13/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7569550 | 0.82 | EPHX1 (0.84) | EPHX1GAAKDM4EALDH1A1EPHX2 | |
| SCHEMBL491868 | 0.79 | EPHX1 (0.79) | EPHX1GAAKDM4EALDH1A1EPHX2 | |
| SCHEMBL1314827 | 0.79 | SIGMAR1 (0.72) | RAD52CHRM5CHRM3SIGMAR1EPHX1 | |
| SCHEMBL1316135 | 0.79 | SIGMAR1 (0.72) | RAD52CHRM5CHRM3SIGMAR1EPHX1 | |
| SCHEMBL15975480 | 0.79 | EPHX1 (0.79) | EPHX1GAAKDM4EALDH1A1EPHX2 | |
| SCHEMBL14761678 | 0.79 | ITGB3 (0.58) | RAD52CHRM5CHRM3SIGMAR1ALDH1A1 | |
| SCHEMBL18230719 | 0.78 | RAD52 (0.55) | RAD52CHRM5CHRM3SIGMAR1EPHX1 | |
| SCHEMBL18230721 | 0.78 | RAD52 (0.55) | RAD52CHRM5CHRM3SIGMAR1EPHX1 | |
| SCHEMBL1316096 | 0.77 | SIGMAR1 (0.69) | RAD52CHRM5CHRM3SIGMAR1EPHX1 | |
| SCHEMBL22064074 | 0.77 | ITGB3 (0.56) | RAD52CHRM5CHRM3SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275670-A1 | New Compounds VII | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | claimed |
| EP-2321276-A1 | NEW COMPOUNDS VII | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | claimed |
| WO-2009147219-A1 | NEW COMPOUNDS VII | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | claimed |
| US-20110275670-A1 | New Compounds VII | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2321276-A1 | NEW COMPOUNDS VII | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009147219-A1 | NEW COMPOUNDS VII | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275670-A1 | New Compounds VII | GPR119, GLP1R, GIPR | RAD52 4604/4885CHRM5 1855/4885CHRM3 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.